These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22253738)

  • 1. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.
    Cafiso V; Bertuccio T; Spina D; Purrello S; Campanile F; Di Pietro C; Purrello M; Stefani S
    PLoS One; 2012; 7(1):e29573. PubMed ID: 22253738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
    Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
    BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
    Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
    Matsuo M; Cui L; Kim J; Hiramatsu K
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin and vancomycin heteroresistance revealed among CC5-SCCmecII MRSA clone and in vitro evaluation of treatment alternatives.
    Okado JB; Avaca-Crusca JS; Oliveira AL; Dabul ANG; Camargo ILBDC
    J Glob Antimicrob Resist; 2018 Sep; 14():209-216. PubMed ID: 29753135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VraR Binding to the Promoter Region of
    Dai Y; Chang W; Zhao C; Peng J; Xu L; Lu H; Zhou S; Ma X
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.
    Saito M; Katayama Y; Hishinuma T; Iwamoto A; Aiba Y; Kuwahara-Arai K; Cui L; Matsuo M; Aritaka N; Hiramatsu K
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5024-35. PubMed ID: 24841271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).
    Thitiananpakorn K; Aiba Y; Tan XE; Watanabe S; Kiga K; Sato'o Y; Boonsiri T; Li FY; Sasahara T; Taki Y; Azam AH; Zhang Y; Cui L
    Sci Rep; 2020 Sep; 10(1):16107. PubMed ID: 32999359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.
    Howden BP; McEvoy CR; Allen DL; Chua K; Gao W; Harrison PF; Bell J; Coombs G; Bennett-Wood V; Porter JL; Robins-Browne R; Davies JK; Seemann T; Stinear TP
    PLoS Pathog; 2011 Nov; 7(11):e1002359. PubMed ID: 22102812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.
    Passalacqua KD; Satola SW; Crispell EK; Read TD
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5212-23. PubMed ID: 22850507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
    Sader HS; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".
    Matsuo M; Hishinuma T; Katayama Y; Hiramatsu K
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4215-25. PubMed ID: 25941225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced vancomycin susceptibility and increased macrophage survival in Staphylococcus aureus strains sequentially isolated from a bacteraemic patient during a short course of antibiotic therapy.
    Basco MDS; Kothari A; McKinzie PB; Revollo JR; Agnihothram S; Azevedo MP; Saccente M; Hart ME
    J Med Microbiol; 2019 Jun; 68(6):848-859. PubMed ID: 31136294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiomics characterization of methicillin-resistant Staphylococcus aureus (MRSA) isolates with heterogeneous intermediate resistance to vancomycin (hVISA) in Latin America.
    Castro BE; Rios R; Carvajal LP; Vargas ML; Cala MP; León L; Hanson B; Dinh AQ; Ortega-Recalde O; Seas C; Munita JM; Arias CA; Rincon S; Reyes J; Diaz L
    J Antimicrob Chemother; 2022 Dec; 78(1):122-132. PubMed ID: 36322484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.
    Howden BP; Peleg AY; Stinear TP
    Infect Genet Evol; 2014 Jan; 21():575-82. PubMed ID: 23567819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental Strain.
    Di Gregorio S; Fernandez S; Cuirolo A; Verlaine O; Amoroso A; Mengin-Lecreulx D; Famiglietti A; Joris B; Mollerach M
    Microb Drug Resist; 2017 Jan; 23(1):44-50. PubMed ID: 27991847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.